Core Viewpoint - The company announced the initiation of preclinical research for CKBA, a novel drug for Alzheimer's disease, highlighting its potential in addressing the growing patient population due to aging demographics [1][3]. Group 1: Alzheimer's Disease Research - Alzheimer's disease (AD) is facing two major challenges: unclear core pathogenic mechanisms and limited breakthroughs in traditional drug targets, necessitating new theoretical frameworks and drug solutions [1]. - The research published in "Nature Aging" reveals the critical role of the "lipid metabolism—microglial activation—neuroinflammation" axis in AD, establishing CKBA's new target MFE-2 as a valuable intervention point for innovative drug development [2]. - CKBA, derived from the active component AKBA of traditional Chinese medicine, has demonstrated a threefold effect in AD model mice: improving cognitive function, reducing neuroinflammation, and decreasing Aβ plaques, overcoming traditional drug limitations [4]. Group 2: Clinical Development Plans - The company plans to advance CKBA into clinical research for Alzheimer's disease, with a goal to initiate Phase I clinical trials in the second half of 2026 if progress is smooth [4]. - CKBA is also being explored for its potential in treating immune-related diseases beyond AD, marking the company's first step into the innovative drug sector [5]. Group 3: Other Indications and Market Potential - The company is conducting Phase III clinical trials for CKBA in treating vitiligo, a chronic autoimmune skin disease, with a significant market potential exceeding 100 billion yuan in China [5]. - CKBA's development for rosacea has also progressed, with plans to start patient medication by the end of the year and aim for new drug application approval by 2027 [6].
泰恩康1.1类创新药CKBA迎新进展 阿尔兹海默症研究获突破